Table 3.

Response to immunosuppresive treatment accoring to IL28B rs12979860 genotype (n = 195).

		PD1.3			IL28B rs12979860
	Total (n = 195)	GG (n = 159)	GA/AA (n = 36)	P value	CC (n = 77)	CT/TT (n = 118)	P value
Treatment schedule
Prednisolone + Mycophenolate mofetil	152 (77.9%)	126 (79.2%)	26 (72.2%)	0.489	61 (79.2%)	91 (77.1%)	0.659
Prednisolone + Azathioprine	26 (13.3%)	19 (11.9%)	7 (19.4%)		11 (14.3%)	15 (12.7%)
Prednisolone only	17 (8.7%)	14 (8.8%)	3 (8.3%)		5 (6.5%)	12 (10.2%)
Treatment duration (months)	63 (77)	66 (69)	62 (74)	0.830	61 (46)	67 (81)	0.172
On-treatment complete response	176 (90.3%)	144 (90.6%)	32 (88.9%)	0.758	72 (93.5%)	104 (88.1%)	0.323
Time to achieve complete response (months)	3 (5)	3 (5)	3 (3)	0.891	2 (4)	3 (5)	0.426
Corticosteroids withdrawal in patients with on-treatment complete.response	86/176 (48.9%)	70/144 (48.6%)	16/32 (52%)	1.000	31/72 (43.1%)	55/104 (52.9%)	0.259
Relapse during treatment after corticosteroids withdrawal	38/86 (44.2%)	32/70 (45.7%	6/16 (37.5%)	0.751	14/31 (45.2%)	24/55 (43.6%)	1.000
Complete treatment withdrawal	46/176 (26.1%)	38/144 (26.4%)	8/32 (25%)	1.000	26/72 (36.1%)	20/104 (19.2%)	0.020
Maintenance of response after complete treatment withdrawal	34/46 (73.9%)	28/38 (73.7%)	6/8 (75%)	1.000	17/26 (65.4%)	17/20 (85%)	0.245

Abbreviations are same as in the text. n, number of patients in each group.